FDA Grants Breakthrough Therapy Designation to Armata’s Phage Therapy for Complicated Staph Blood Infections
FDA awards Breakthrough Therapy designation to Armata’s AP-SA02 for adjunct treatment of complicated staph bacteremia, including MRSA.
/ 3 items
#ARMP↓
Armata Clears Key FDA Milestone, Prepares AP-SA02 Phase 3 Trial for 2026
Armata Pharmaceuticals reaches key regulatory milestone with FDA submission for AP-SA02 Phase 3 trial. Lead bacteriophage candidate targets serious S. aureus infections with new DoD funding.
Armata Pharmaceuticals Shows Promising Results for AP-SA02 in Severe Staph Infection
Armata's AP-SA02 bacteriophage cocktail showed high cure rates and zero relapse in a Phase 2 trial for complicated Staphylococcus aureus bacteremia (SAB), signaling a potential new standard of care.